Denali Therapeutics Inc.
Denali Therapeutics Inc. (DNLI) Stock Competitors & Peer Comparison
See (DNLI) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DNLI | $14.29 | -1.04% | 2.1B | -4.98 | -$2.87 | N/A |
| VRTX | $374.98 | -20.60% | 96.3B | -97.91 | -$3.83 | N/A |
| REGN | $569.90 | -0.29% | 60.5B | 14.04 | $40.58 | +0.31% |
| ALNY | $418.91 | -0.15% | 54.9B | -168.92 | -$2.48 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ARGX | $674.90 | -2.23% | 41.3B | 34.31 | $19.67 | N/A |
| BNTX | $111.07 | +0.95% | 26.7B | -66.91 | -$1.66 | N/A |
| SMMT | $29.13 | -0.65% | 21.6B | -85.68 | -$0.34 | N/A |
| RPRX | $37.91 | +0.08% | 21.3B | 15.47 | $2.45 | +2.27% |
| BGNE | $184.71 | +0.49% | 20.2B | -22.55 | -$8.19 | N/A |
Stock Comparison
DNLI vs VRTX Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, VRTX has a market cap of 96.3B. Regarding current trading prices, DNLI is priced at $14.29, while VRTX trades at $374.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas VRTX's P/E ratio is -97.91. In terms of profitability, DNLI's ROE is -0.36%, compared to VRTX's ROE of +0.20%. Regarding short-term risk, DNLI is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for DNLI.Check VRTX's competition here
DNLI vs REGN Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, REGN has a market cap of 60.5B. Regarding current trading prices, DNLI is priced at $14.29, while REGN trades at $569.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas REGN's P/E ratio is 14.04. In terms of profitability, DNLI's ROE is -0.36%, compared to REGN's ROE of +0.14%. Regarding short-term risk, DNLI is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check REGN's competition here
DNLI vs ALNY Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, ALNY has a market cap of 54.9B. Regarding current trading prices, DNLI is priced at $14.29, while ALNY trades at $418.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas ALNY's P/E ratio is -168.92. In terms of profitability, DNLI's ROE is -0.36%, compared to ALNY's ROE of -2.74%. Regarding short-term risk, DNLI is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check ALNY's competition here
DNLI vs SGEN Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, DNLI is priced at $14.29, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas SGEN's P/E ratio is -57.19. In terms of profitability, DNLI's ROE is -0.36%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, DNLI is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check SGEN's competition here
DNLI vs ARGX Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, ARGX has a market cap of 41.3B. Regarding current trading prices, DNLI is priced at $14.29, while ARGX trades at $674.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas ARGX's P/E ratio is 34.31. In terms of profitability, DNLI's ROE is -0.36%, compared to ARGX's ROE of +0.23%. Regarding short-term risk, DNLI is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check ARGX's competition here
DNLI vs BNTX Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, BNTX has a market cap of 26.7B. Regarding current trading prices, DNLI is priced at $14.29, while BNTX trades at $111.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas BNTX's P/E ratio is -66.91. In terms of profitability, DNLI's ROE is -0.36%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, DNLI is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check BNTX's competition here
DNLI vs SMMT Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, SMMT has a market cap of 21.6B. Regarding current trading prices, DNLI is priced at $14.29, while SMMT trades at $29.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas SMMT's P/E ratio is -85.68. In terms of profitability, DNLI's ROE is -0.36%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, DNLI is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for DNLI.Check SMMT's competition here
DNLI vs RPRX Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, RPRX has a market cap of 21.3B. Regarding current trading prices, DNLI is priced at $14.29, while RPRX trades at $37.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas RPRX's P/E ratio is 15.47. In terms of profitability, DNLI's ROE is -0.36%, compared to RPRX's ROE of +0.16%. Regarding short-term risk, DNLI is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check RPRX's competition here
DNLI vs BGNE Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, DNLI is priced at $14.29, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas BGNE's P/E ratio is -22.55. In terms of profitability, DNLI's ROE is -0.36%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, DNLI is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check BGNE's competition here
DNLI vs DNA-WT Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, DNLI is priced at $14.29, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, DNLI's ROE is -0.36%, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, DNLI is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for DNLI.Check DNA-WT's competition here
DNLI vs INCY Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, INCY has a market cap of 15.2B. Regarding current trading prices, DNLI is priced at $14.29, while INCY trades at $77.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas INCY's P/E ratio is 18.37. In terms of profitability, DNLI's ROE is -0.36%, compared to INCY's ROE of +0.34%. Regarding short-term risk, DNLI is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check INCY's competition here
DNLI vs UTHR Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, UTHR has a market cap of 13.8B. Regarding current trading prices, DNLI is priced at $14.29, while UTHR trades at $304.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas UTHR's P/E ratio is 11.89. In terms of profitability, DNLI's ROE is -0.36%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, DNLI is less volatile compared to UTHR. This indicates potentially lower risk in terms of short-term price fluctuations for DNLI.Check UTHR's competition here
DNLI vs GMAB Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, GMAB has a market cap of 13.6B. Regarding current trading prices, DNLI is priced at $14.29, while GMAB trades at $22.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas GMAB's P/E ratio is 13.00. In terms of profitability, DNLI's ROE is -0.36%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, DNLI is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check GMAB's competition here
DNLI vs KRTX Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, DNLI is priced at $14.29, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas KRTX's P/E ratio is -28.09. In terms of profitability, DNLI's ROE is -0.36%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, DNLI is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check KRTX's competition here
DNLI vs BMRN Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, BMRN has a market cap of 11.9B. Regarding current trading prices, DNLI is priced at $14.29, while BMRN trades at $61.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas BMRN's P/E ratio is 22.94. In terms of profitability, DNLI's ROE is -0.36%, compared to BMRN's ROE of +0.11%. Regarding short-term risk, DNLI is less volatile compared to BMRN. This indicates potentially lower risk in terms of short-term price fluctuations for DNLI.Check BMRN's competition here
DNLI vs ASND Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, ASND has a market cap of 11.3B. Regarding current trading prices, DNLI is priced at $14.29, while ASND trades at $186.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas ASND's P/E ratio is -28.06. In terms of profitability, DNLI's ROE is -0.36%, compared to ASND's ROE of +1.91%. Regarding short-term risk, DNLI is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check ASND's competition here
DNLI vs MRNA Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, MRNA has a market cap of 10.6B. Regarding current trading prices, DNLI is priced at $14.29, while MRNA trades at $27.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas MRNA's P/E ratio is -3.65. In terms of profitability, DNLI's ROE is -0.36%, compared to MRNA's ROE of -0.27%. Regarding short-term risk, DNLI is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check MRNA's competition here
DNLI vs EXEL Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, EXEL has a market cap of 10.1B. Regarding current trading prices, DNLI is priced at $14.29, while EXEL trades at $37.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas EXEL's P/E ratio is 18.01. In terms of profitability, DNLI's ROE is -0.36%, compared to EXEL's ROE of +0.28%. Regarding short-term risk, DNLI is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check EXEL's competition here
DNLI vs RXDX Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, DNLI is priced at $14.29, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas RXDX's P/E ratio is -56.47. In terms of profitability, DNLI's ROE is -0.36%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, DNLI is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check RXDX's competition here
DNLI vs BBIO Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, BBIO has a market cap of 9.3B. Regarding current trading prices, DNLI is priced at $14.29, while BBIO trades at $49.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas BBIO's P/E ratio is -13.82. In terms of profitability, DNLI's ROE is -0.36%, compared to BBIO's ROE of +0.49%. Regarding short-term risk, DNLI is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for DNLI.Check BBIO's competition here
DNLI vs VRNA Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, VRNA has a market cap of 9B. Regarding current trading prices, DNLI is priced at $14.29, while VRNA trades at $105.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas VRNA's P/E ratio is -52.70. In terms of profitability, DNLI's ROE is -0.36%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, DNLI is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check VRNA's competition here
DNLI vs IMGN Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, DNLI is priced at $14.29, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas IMGN's P/E ratio is -111.55. In terms of profitability, DNLI's ROE is -0.36%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, DNLI is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check IMGN's competition here
DNLI vs TECH Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, TECH has a market cap of 8.6B. Regarding current trading prices, DNLI is priced at $14.29, while TECH trades at $54.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas TECH's P/E ratio is 65.83. In terms of profitability, DNLI's ROE is -0.36%, compared to TECH's ROE of +0.06%. Regarding short-term risk, DNLI is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check TECH's competition here
DNLI vs BPMC Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, DNLI is priced at $14.29, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas BPMC's P/E ratio is -51.58. In terms of profitability, DNLI's ROE is -0.36%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, DNLI is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check BPMC's competition here
DNLI vs CERE Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, DNLI is priced at $14.29, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas CERE's P/E ratio is -16.47. In terms of profitability, DNLI's ROE is -0.36%, compared to CERE's ROE of -0.43%. Regarding short-term risk, DNLI is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check CERE's competition here
DNLI vs ROIV Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, ROIV has a market cap of 7.9B. Regarding current trading prices, DNLI is priced at $14.29, while ROIV trades at $11.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas ROIV's P/E ratio is -15.51. In terms of profitability, DNLI's ROE is -0.36%, compared to ROIV's ROE of -0.03%. Regarding short-term risk, DNLI is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check ROIV's competition here
DNLI vs ROIVW Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, DNLI is priced at $14.29, while ROIVW trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, DNLI's ROE is -0.36%, compared to ROIVW's ROE of -0.03%. Regarding short-term risk, DNLI is less volatile compared to ROIVW. This indicates potentially lower risk in terms of short-term price fluctuations for DNLI.Check ROIVW's competition here
DNLI vs MDGL Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, MDGL has a market cap of 7.5B. Regarding current trading prices, DNLI is priced at $14.29, while MDGL trades at $338.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas MDGL's P/E ratio is -18.99. In terms of profitability, DNLI's ROE is -0.36%, compared to MDGL's ROE of -0.38%. Regarding short-term risk, DNLI is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for DNLI.Check MDGL's competition here
DNLI vs HALO Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, HALO has a market cap of 7.5B. Regarding current trading prices, DNLI is priced at $14.29, while HALO trades at $60.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas HALO's P/E ratio is 16.17. In terms of profitability, DNLI's ROE is -0.36%, compared to HALO's ROE of +1.22%. Regarding short-term risk, DNLI is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check HALO's competition here
DNLI vs CORT Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, CORT has a market cap of 7.4B. Regarding current trading prices, DNLI is priced at $14.29, while CORT trades at $70.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas CORT's P/E ratio is 62.90. In terms of profitability, DNLI's ROE is -0.36%, compared to CORT's ROE of +0.20%. Regarding short-term risk, DNLI is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check CORT's competition here
DNLI vs RVMD Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, RVMD has a market cap of 7.2B. Regarding current trading prices, DNLI is priced at $14.29, while RVMD trades at $38.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas RVMD's P/E ratio is -9.57. In terms of profitability, DNLI's ROE is -0.36%, compared to RVMD's ROE of -0.37%. Regarding short-term risk, DNLI is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for DNLI.Check RVMD's competition here
DNLI vs IONS Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, IONS has a market cap of 6.9B. Regarding current trading prices, DNLI is priced at $14.29, while IONS trades at $43.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas IONS's P/E ratio is -24.46. In terms of profitability, DNLI's ROE is -0.36%, compared to IONS's ROE of -0.45%. Regarding short-term risk, DNLI is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check IONS's competition here
DNLI vs JAZZ Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, JAZZ has a market cap of 6.8B. Regarding current trading prices, DNLI is priced at $14.29, while JAZZ trades at $113.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas JAZZ's P/E ratio is 15.38. In terms of profitability, DNLI's ROE is -0.36%, compared to JAZZ's ROE of +0.12%. Regarding short-term risk, DNLI is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check JAZZ's competition here
DNLI vs RETA Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, DNLI is priced at $14.29, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas RETA's P/E ratio is -66.29. In terms of profitability, DNLI's ROE is -0.36%, compared to RETA's ROE of +0.47%. Regarding short-term risk, DNLI is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check RETA's competition here
DNLI vs RYTM Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, RYTM has a market cap of 5.8B. Regarding current trading prices, DNLI is priced at $14.29, while RYTM trades at $88.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas RYTM's P/E ratio is -30.97. In terms of profitability, DNLI's ROE is -0.36%, compared to RYTM's ROE of -1.78%. Regarding short-term risk, DNLI is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for DNLI.Check RYTM's competition here
DNLI vs NUVL Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, NUVL has a market cap of 5.6B. Regarding current trading prices, DNLI is priced at $14.29, while NUVL trades at $78.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas NUVL's P/E ratio is -17.79. In terms of profitability, DNLI's ROE is -0.36%, compared to NUVL's ROE of -0.31%. Regarding short-term risk, DNLI is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check NUVL's competition here
DNLI vs ABCM Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, DNLI is priced at $14.29, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, DNLI's ROE is -0.36%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, DNLI is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check ABCM's competition here
DNLI vs ISEE Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, DNLI is priced at $14.29, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas ISEE's P/E ratio is -22.44. In terms of profitability, DNLI's ROE is -0.36%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, DNLI is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check ISEE's competition here
DNLI vs ABVX Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, ABVX has a market cap of 5.3B. Regarding current trading prices, DNLI is priced at $14.29, while ABVX trades at $70.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas ABVX's P/E ratio is -20.98. In terms of profitability, DNLI's ROE is -0.36%, compared to ABVX's ROE of -1.06%. Regarding short-term risk, DNLI is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for DNLI.Check ABVX's competition here
DNLI vs AXSM Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, AXSM has a market cap of 5.1B. Regarding current trading prices, DNLI is priced at $14.29, while AXSM trades at $103.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas AXSM's P/E ratio is -20.47. In terms of profitability, DNLI's ROE is -0.36%, compared to AXSM's ROE of -3.58%. Regarding short-term risk, DNLI is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for DNLI.Check AXSM's competition here
DNLI vs MRUS Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, MRUS has a market cap of 5B. Regarding current trading prices, DNLI is priced at $14.29, while MRUS trades at $67.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas MRUS's P/E ratio is -15.87. In terms of profitability, DNLI's ROE is -0.36%, compared to MRUS's ROE of -0.41%. Regarding short-term risk, DNLI is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check MRUS's competition here
DNLI vs CRSP Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, CRSP has a market cap of 4.8B. Regarding current trading prices, DNLI is priced at $14.29, while CRSP trades at $55.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas CRSP's P/E ratio is -12.38. In terms of profitability, DNLI's ROE is -0.36%, compared to CRSP's ROE of -0.25%. Regarding short-term risk, DNLI is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for DNLI.Check CRSP's competition here
DNLI vs RNA Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, RNA has a market cap of 4.6B. Regarding current trading prices, DNLI is priced at $14.29, while RNA trades at $38.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas RNA's P/E ratio is -12.75. In terms of profitability, DNLI's ROE is -0.36%, compared to RNA's ROE of -0.27%. Regarding short-term risk, DNLI is more volatile compared to RNA. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check RNA's competition here
DNLI vs ADMA Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, ADMA has a market cap of 4.5B. Regarding current trading prices, DNLI is priced at $14.29, while ADMA trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas ADMA's P/E ratio is 22.57. In terms of profitability, DNLI's ROE is -0.36%, compared to ADMA's ROE of +0.72%. Regarding short-term risk, DNLI is less volatile compared to ADMA. This indicates potentially lower risk in terms of short-term price fluctuations for DNLI.Check ADMA's competition here
DNLI vs TGTX Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, TGTX has a market cap of 4.5B. Regarding current trading prices, DNLI is priced at $14.29, while TGTX trades at $28.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas TGTX's P/E ratio is 74.74. In terms of profitability, DNLI's ROE is -0.36%, compared to TGTX's ROE of +0.29%. Regarding short-term risk, DNLI is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for DNLI.Check TGTX's competition here
DNLI vs ALPN Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, DNLI is priced at $14.29, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas ALPN's P/E ratio is -101.52. In terms of profitability, DNLI's ROE is -0.36%, compared to ALPN's ROE of -0.04%. Regarding short-term risk, DNLI is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check ALPN's competition here
DNLI vs ALKS Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, ALKS has a market cap of 4.4B. Regarding current trading prices, DNLI is priced at $14.29, while ALKS trades at $26.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas ALKS's P/E ratio is 12.85. In terms of profitability, DNLI's ROE is -0.36%, compared to ALKS's ROE of +0.24%. Regarding short-term risk, DNLI is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check ALKS's competition here
DNLI vs ZLAB Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, ZLAB has a market cap of 4.4B. Regarding current trading prices, DNLI is priced at $14.29, while ZLAB trades at $39.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas ZLAB's P/E ratio is -15.80. In terms of profitability, DNLI's ROE is -0.36%, compared to ZLAB's ROE of -0.33%. Regarding short-term risk, DNLI is more volatile compared to ZLAB. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check ZLAB's competition here
DNLI vs PCVX Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, PCVX has a market cap of 4.4B. Regarding current trading prices, DNLI is priced at $14.29, while PCVX trades at $33.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas PCVX's P/E ratio is -8.45. In terms of profitability, DNLI's ROE is -0.36%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, DNLI is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check PCVX's competition here
DNLI vs CYTK Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, CYTK has a market cap of 4.3B. Regarding current trading prices, DNLI is priced at $14.29, while CYTK trades at $36.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas CYTK's P/E ratio is -6.84. In terms of profitability, DNLI's ROE is -0.36%, compared to CYTK's ROE of +8.01%. Regarding short-term risk, DNLI is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check CYTK's competition here
DNLI vs SLNO Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, SLNO has a market cap of 4.3B. Regarding current trading prices, DNLI is priced at $14.29, while SLNO trades at $81.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas SLNO's P/E ratio is -17.22. In terms of profitability, DNLI's ROE is -0.36%, compared to SLNO's ROE of -0.78%. Regarding short-term risk, DNLI is more volatile compared to SLNO. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check SLNO's competition here
DNLI vs OPT Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, DNLI is priced at $14.29, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas OPT's P/E ratio is -1.52. In terms of profitability, DNLI's ROE is -0.36%, compared to OPT's ROE of +2.60%. Regarding short-term risk, DNLI is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check OPT's competition here
DNLI vs TLX Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, TLX has a market cap of 4.1B. Regarding current trading prices, DNLI is priced at $14.29, while TLX trades at $12.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas TLX's P/E ratio is 136.22. In terms of profitability, DNLI's ROE is -0.36%, compared to TLX's ROE of +0.06%. Regarding short-term risk, DNLI is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check TLX's competition here
DNLI vs MRTX Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, DNLI is priced at $14.29, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas MRTX's P/E ratio is -4.82. In terms of profitability, DNLI's ROE is -0.36%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, DNLI is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check MRTX's competition here
DNLI vs PTCT Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, PTCT has a market cap of 4.1B. Regarding current trading prices, DNLI is priced at $14.29, while PTCT trades at $51.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas PTCT's P/E ratio is 7.85. In terms of profitability, DNLI's ROE is -0.36%, compared to PTCT's ROE of -0.72%. Regarding short-term risk, DNLI is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check PTCT's competition here
DNLI vs ACLX Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, ACLX has a market cap of 4B. Regarding current trading prices, DNLI is priced at $14.29, while ACLX trades at $72.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas ACLX's P/E ratio is -24.09. In terms of profitability, DNLI's ROE is -0.36%, compared to ACLX's ROE of -0.35%. Regarding short-term risk, DNLI is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check ACLX's competition here
DNLI vs KRYS Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, KRYS has a market cap of 4B. Regarding current trading prices, DNLI is priced at $14.29, while KRYS trades at $137.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas KRYS's P/E ratio is 38.26. In terms of profitability, DNLI's ROE is -0.36%, compared to KRYS's ROE of +0.15%. Regarding short-term risk, DNLI is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for DNLI.Check KRYS's competition here
DNLI vs ACAD Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, ACAD has a market cap of 4B. Regarding current trading prices, DNLI is priced at $14.29, while ACAD trades at $23.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas ACAD's P/E ratio is 17.26. In terms of profitability, DNLI's ROE is -0.36%, compared to ACAD's ROE of +0.35%. Regarding short-term risk, DNLI is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check ACAD's competition here
DNLI vs AKRO Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, AKRO has a market cap of 4B. Regarding current trading prices, DNLI is priced at $14.29, while AKRO trades at $49.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas AKRO's P/E ratio is -13.15. In terms of profitability, DNLI's ROE is -0.36%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, DNLI is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check AKRO's competition here
DNLI vs AAPG Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, AAPG has a market cap of 3.9B. Regarding current trading prices, DNLI is priced at $14.29, while AAPG trades at $42.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas AAPG's P/E ratio is -57.28. In terms of profitability, DNLI's ROE is -0.36%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, DNLI is less volatile compared to AAPG. This indicates potentially lower risk in terms of short-term price fluctuations for DNLI.Check AAPG's competition here
DNLI vs VKTX Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, VKTX has a market cap of 3.8B. Regarding current trading prices, DNLI is priced at $14.29, while VKTX trades at $34.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas VKTX's P/E ratio is -22.10. In terms of profitability, DNLI's ROE is -0.36%, compared to VKTX's ROE of -0.20%. Regarding short-term risk, DNLI is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check VKTX's competition here
DNLI vs RYZB Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, DNLI is priced at $14.29, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas RYZB's P/E ratio is -57.86. In terms of profitability, DNLI's ROE is -0.36%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, DNLI is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check RYZB's competition here
DNLI vs CBAY Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, DNLI is priced at $14.29, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas CBAY's P/E ratio is -32.81. In terms of profitability, DNLI's ROE is -0.36%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, DNLI is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check CBAY's competition here
DNLI vs SWTX Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, DNLI is priced at $14.29, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas SWTX's P/E ratio is -13.78. In terms of profitability, DNLI's ROE is -0.36%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, DNLI is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check SWTX's competition here
DNLI vs LEGN Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, LEGN has a market cap of 3.5B. Regarding current trading prices, DNLI is priced at $14.29, while LEGN trades at $38.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas LEGN's P/E ratio is -32.84. In terms of profitability, DNLI's ROE is -0.36%, compared to LEGN's ROE of -0.20%. Regarding short-term risk, DNLI is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check LEGN's competition here
DNLI vs SRRK Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, SRRK has a market cap of 3.5B. Regarding current trading prices, DNLI is priced at $14.29, while SRRK trades at $36.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas SRRK's P/E ratio is -14.50. In terms of profitability, DNLI's ROE is -0.36%, compared to SRRK's ROE of -1.18%. Regarding short-term risk, DNLI is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check SRRK's competition here
DNLI vs MTSR Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, MTSR has a market cap of 3.5B. Regarding current trading prices, DNLI is priced at $14.29, while MTSR trades at $33.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas MTSR's P/E ratio is -11.50. In terms of profitability, DNLI's ROE is -0.36%, compared to MTSR's ROE of -0.90%. Regarding short-term risk, DNLI is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for DNLI.Check MTSR's competition here
DNLI vs MLTX Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, MLTX has a market cap of 3.4B. Regarding current trading prices, DNLI is priced at $14.29, while MLTX trades at $53.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas MLTX's P/E ratio is -23.22. In terms of profitability, DNLI's ROE is -0.36%, compared to MLTX's ROE of -0.31%. Regarding short-term risk, DNLI is more volatile compared to MLTX. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check MLTX's competition here
DNLI vs PTGX Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, PTGX has a market cap of 3.3B. Regarding current trading prices, DNLI is priced at $14.29, while PTGX trades at $53.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas PTGX's P/E ratio is 69.10. In terms of profitability, DNLI's ROE is -0.36%, compared to PTGX's ROE of +0.09%. Regarding short-term risk, DNLI is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for DNLI.Check PTGX's competition here
DNLI vs APLS Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, APLS has a market cap of 3.1B. Regarding current trading prices, DNLI is priced at $14.29, while APLS trades at $24.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas APLS's P/E ratio is -13.22. In terms of profitability, DNLI's ROE is -0.36%, compared to APLS's ROE of -1.16%. Regarding short-term risk, DNLI is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check APLS's competition here
DNLI vs KYMR Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, KYMR has a market cap of 3B. Regarding current trading prices, DNLI is priced at $14.29, while KYMR trades at $42.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas KYMR's P/E ratio is -13.82. In terms of profitability, DNLI's ROE is -0.36%, compared to KYMR's ROE of -0.30%. Regarding short-term risk, DNLI is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check KYMR's competition here
DNLI vs MORF Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, DNLI is priced at $14.29, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas MORF's P/E ratio is -14.88. In terms of profitability, DNLI's ROE is -0.36%, compared to MORF's ROE of -0.22%. Regarding short-term risk, DNLI is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check MORF's competition here
DNLI vs MOR Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, DNLI is priced at $14.29, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas MOR's P/E ratio is -12.64. In terms of profitability, DNLI's ROE is -0.36%, compared to MOR's ROE of -1.84%. Regarding short-term risk, DNLI is more volatile compared to MOR. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check MOR's competition here
DNLI vs IMVT Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, IMVT has a market cap of 2.8B. Regarding current trading prices, DNLI is priced at $14.29, while IMVT trades at $16.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas IMVT's P/E ratio is -6.05. In terms of profitability, DNLI's ROE is -0.36%, compared to IMVT's ROE of -0.81%. Regarding short-term risk, DNLI is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for DNLI.Check IMVT's competition here
DNLI vs CRNX Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, CRNX has a market cap of 2.7B. Regarding current trading prices, DNLI is priced at $14.29, while CRNX trades at $29.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas CRNX's P/E ratio is -7.69. In terms of profitability, DNLI's ROE is -0.36%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, DNLI is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for DNLI.Check CRNX's competition here
DNLI vs RARE Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, RARE has a market cap of 2.7B. Regarding current trading prices, DNLI is priced at $14.29, while RARE trades at $28.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas RARE's P/E ratio is -4.96. In terms of profitability, DNLI's ROE is -0.36%, compared to RARE's ROE of -1.86%. Regarding short-term risk, DNLI is less volatile compared to RARE. This indicates potentially lower risk in terms of short-term price fluctuations for DNLI.Check RARE's competition here
DNLI vs CPRX Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, CPRX has a market cap of 2.7B. Regarding current trading prices, DNLI is priced at $14.29, while CPRX trades at $22.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas CPRX's P/E ratio is 13.80. In terms of profitability, DNLI's ROE is -0.36%, compared to CPRX's ROE of +0.28%. Regarding short-term risk, DNLI is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check CPRX's competition here
DNLI vs KDNY Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, DNLI is priced at $14.29, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas KDNY's P/E ratio is -12.47. In terms of profitability, DNLI's ROE is -0.36%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, DNLI is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check KDNY's competition here
DNLI vs XENE Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, XENE has a market cap of 2.6B. Regarding current trading prices, DNLI is priced at $14.29, while XENE trades at $34.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas XENE's P/E ratio is -10.68. In terms of profitability, DNLI's ROE is -0.36%, compared to XENE's ROE of -0.32%. Regarding short-term risk, DNLI is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for DNLI.Check XENE's competition here
DNLI vs MYOV Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, DNLI is priced at $14.29, while MYOV trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas MYOV's P/E ratio is -14.05. In terms of profitability, DNLI's ROE is -0.36%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, DNLI is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check MYOV's competition here
DNLI vs LGND Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, LGND has a market cap of 2.6B. Regarding current trading prices, DNLI is priced at $14.29, while LGND trades at $135.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas LGND's P/E ratio is -18.54. In terms of profitability, DNLI's ROE is -0.36%, compared to LGND's ROE of -0.16%. Regarding short-term risk, DNLI is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check LGND's competition here
DNLI vs MIRM Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, MIRM has a market cap of 2.6B. Regarding current trading prices, DNLI is priced at $14.29, while MIRM trades at $51.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas MIRM's P/E ratio is -32.20. In terms of profitability, DNLI's ROE is -0.36%, compared to MIRM's ROE of -0.34%. Regarding short-term risk, DNLI is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check MIRM's competition here
DNLI vs KNSA Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, KNSA has a market cap of 2.5B. Regarding current trading prices, DNLI is priced at $14.29, while KNSA trades at $33.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas KNSA's P/E ratio is 661.40. In terms of profitability, DNLI's ROE is -0.36%, compared to KNSA's ROE of +0.01%. Regarding short-term risk, DNLI is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check KNSA's competition here
DNLI vs NAMS Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, NAMS has a market cap of 2.4B. Regarding current trading prices, DNLI is priced at $14.29, while NAMS trades at $21.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas NAMS's P/E ratio is -11.81. In terms of profitability, DNLI's ROE is -0.36%, compared to NAMS's ROE of -0.33%. Regarding short-term risk, DNLI is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check NAMS's competition here
DNLI vs PRVB Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, DNLI is priced at $14.29, while PRVB trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas PRVB's P/E ratio is -16.43. In terms of profitability, DNLI's ROE is -0.36%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, DNLI is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check PRVB's competition here
DNLI vs RXRX Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, RXRX has a market cap of 2.4B. Regarding current trading prices, DNLI is priced at $14.29, while RXRX trades at $5.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas RXRX's P/E ratio is -3.07. In terms of profitability, DNLI's ROE is -0.36%, compared to RXRX's ROE of -0.76%. Regarding short-term risk, DNLI is less volatile compared to RXRX. This indicates potentially lower risk in terms of short-term price fluctuations for DNLI.Check RXRX's competition here
DNLI vs LBPH Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, DNLI is priced at $14.29, while LBPH trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas LBPH's P/E ratio is -26.66. In terms of profitability, DNLI's ROE is -0.36%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, DNLI is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check LBPH's competition here
DNLI vs NAMSW Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, NAMSW has a market cap of 2.3B. Regarding current trading prices, DNLI is priced at $14.29, while NAMSW trades at $10.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas NAMSW's P/E ratio is N/A. In terms of profitability, DNLI's ROE is -0.36%, compared to NAMSW's ROE of -0.33%. Regarding short-term risk, DNLI is less volatile compared to NAMSW. This indicates potentially lower risk in terms of short-term price fluctuations for DNLI.Check NAMSW's competition here
DNLI vs CNTA Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, CNTA has a market cap of 2.3B. Regarding current trading prices, DNLI is priced at $14.29, while CNTA trades at $17.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas CNTA's P/E ratio is -9.21. In terms of profitability, DNLI's ROE is -0.36%, compared to CNTA's ROE of -0.57%. Regarding short-term risk, DNLI is less volatile compared to CNTA. This indicates potentially lower risk in terms of short-term price fluctuations for DNLI.Check CNTA's competition here
DNLI vs APGE Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, APGE has a market cap of 2.3B. Regarding current trading prices, DNLI is priced at $14.29, while APGE trades at $38.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas APGE's P/E ratio is -10.77. In terms of profitability, DNLI's ROE is -0.36%, compared to APGE's ROE of -0.19%. Regarding short-term risk, DNLI is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for DNLI.Check APGE's competition here
DNLI vs ARWR Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, ARWR has a market cap of 2.3B. Regarding current trading prices, DNLI is priced at $14.29, while ARWR trades at $16.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas ARWR's P/E ratio is -13.28. In terms of profitability, DNLI's ROE is -0.36%, compared to ARWR's ROE of -0.46%. Regarding short-term risk, DNLI is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check ARWR's competition here
DNLI vs DICE Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, DNLI is priced at $14.29, while DICE trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas DICE's P/E ratio is -21.91. In terms of profitability, DNLI's ROE is -0.36%, compared to DICE's ROE of +0.56%. Regarding short-term risk, DNLI is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check DICE's competition here
DNLI vs IBRX Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, IBRX has a market cap of 2.2B. Regarding current trading prices, DNLI is priced at $14.29, while IBRX trades at $2.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas IBRX's P/E ratio is -4.16. In terms of profitability, DNLI's ROE is -0.36%, compared to IBRX's ROE of +0.65%. Regarding short-term risk, DNLI is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check IBRX's competition here
DNLI vs GLPG Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, GLPG has a market cap of 2.2B. Regarding current trading prices, DNLI is priced at $14.29, while GLPG trades at $32.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas GLPG's P/E ratio is -6.46. In terms of profitability, DNLI's ROE is -0.36%, compared to GLPG's ROE of -0.10%. Regarding short-term risk, DNLI is less volatile compared to GLPG. This indicates potentially lower risk in terms of short-term price fluctuations for DNLI.Check GLPG's competition here
DNLI vs BLTE Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, BLTE has a market cap of 2.2B. Regarding current trading prices, DNLI is priced at $14.29, while BLTE trades at $66.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas BLTE's P/E ratio is -46.05. In terms of profitability, DNLI's ROE is -0.36%, compared to BLTE's ROE of -0.32%. Regarding short-term risk, DNLI is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for DNLI.Check BLTE's competition here
DNLI vs FOLD Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, FOLD has a market cap of 2.2B. Regarding current trading prices, DNLI is priced at $14.29, while FOLD trades at $6.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas FOLD's P/E ratio is -58.25. In terms of profitability, DNLI's ROE is -0.36%, compared to FOLD's ROE of -0.20%. Regarding short-term risk, DNLI is less volatile compared to FOLD. This indicates potentially lower risk in terms of short-term price fluctuations for DNLI.Check FOLD's competition here
DNLI vs CALT Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, DNLI is priced at $14.29, while CALT trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas CALT's P/E ratio is -22.73. In terms of profitability, DNLI's ROE is -0.36%, compared to CALT's ROE of -1.67%. Regarding short-term risk, DNLI is less volatile compared to CALT. This indicates potentially lower risk in terms of short-term price fluctuations for DNLI.Check CALT's competition here
DNLI vs IDYA Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, IDYA has a market cap of 2.1B. Regarding current trading prices, DNLI is priced at $14.29, while IDYA trades at $24.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas IDYA's P/E ratio is -6.61. In terms of profitability, DNLI's ROE is -0.36%, compared to IDYA's ROE of -0.29%. Regarding short-term risk, DNLI is less volatile compared to IDYA. This indicates potentially lower risk in terms of short-term price fluctuations for DNLI.Check IDYA's competition here
DNLI vs IRON Comparison August 2025
DNLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNLI stands at 2.1B. In comparison, IRON has a market cap of 2.1B. Regarding current trading prices, DNLI is priced at $14.29, while IRON trades at $60.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNLI currently has a P/E ratio of -4.98, whereas IRON's P/E ratio is -15.40. In terms of profitability, DNLI's ROE is -0.36%, compared to IRON's ROE of -0.23%. Regarding short-term risk, DNLI is more volatile compared to IRON. This indicates potentially higher risk in terms of short-term price fluctuations for DNLI.Check IRON's competition here